Form 4: Acrivon Therapeutics Chief Legal Officer Reports Stock Transaction
SEC Form 4 Filing
Mary Miller, Chief Legal Officer of Acrivon Therapeutics, reports the disposal of 558 shares of common stock to cover tax obligations upon vesting of restricted stock units.
Summary
- On April 17, 2025, Mary Miller, the Chief Legal Officer of Acrivon Therapeutics, Inc., disposed of 558 shares of common stock.
- The transaction was executed to satisfy mandatory tax withholding requirements upon the vesting of restricted stock units.
- The shares were disposed of at a price of $1.81 per share.
- Following the transaction, Miller directly owns 36,507 shares of Acrivon Therapeutics common stock.
Sentiment
Score: 5
Explanation: This is a routine transaction related to tax obligations, so the sentiment is neutral.
Industry Context
Form 4 filings are a routine part of insider trading regulations, providing transparency into the transactions of company executives and directors. This filing indicates a standard tax withholding procedure related to equity compensation.
Key Dates
| Date | Description |
|---|---|
| 04/17/2025 | Date of stock transaction (disposal of shares). |
| 04/18/2025 | Date of signature for the Form 4 filing. |
Keywords
Acrivon Therapeutics, Form 4, Stock Transaction, Mary Miller, Chief Legal Officer, Tax Withholding, Restricted Stock Units, ACRV
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.